Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

[A case of neuromyelitis optica presenting ileus as a neurologic finding].
Differential Diagnosis of White Matter Lesions: Nonvascular Causes-Part II.
More than just multiple sclerosis.
Erratum.
Mitochondrial dysfunction in central nervous system white matter disorders.
Evidence for a two-stage disability progression in multiple sclerosis.
Grey matter lesions in MS: From histology to clinical implications.
The Prevalence of the Classical and non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients.
The role of IFNβ in the treatment of MSand EAE - In the perspective of inflammasomes.
Cognitive reserve and symptom experience in multiple sclerosis: A buffer to disability progression over time?
FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.
Treatment Update in Multiple Sclerosis.
Multiple sclerosis in diverse populations: characteristics in distinct Arab ethnicities in Israel.
Cerebrospinal hepatocyte growth factor levels correlate negatively with disease activity in multiple sclerosis.
Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neuromyelitis Optica.
Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.
The induction of Treg cells by gut-indigenous Clostridium.
Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain.
Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15.
Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature.
[Review on domestic published papers regarding the acute disseminated encephalomyelitis and its relations with rabies vaccination].
Clinically Isolated Syndrome Suggestive of Multiple Sclerosis: Dynamic Patterns of Gray and White Matter Changes-A 2-year MR Imaging Study.
Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.
The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.
Translocator Protein 18 kDa (TSPO) Expression in Multiple Sclerosis Patients.

Pages